Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Jae Duck ChoiTag Keun YooJung Yoon KangHyuk-Dal JungJun Ho LeePublished in: International urology and nephrology (2023)
Adherence to combination BPH therapy is relatively low. Although patients adhered to combination therapy for more than 1 year, a higher risk of requiring prostate surgery or resuming combination therapy was observed in patients who discontinued 5ARI.
Keyphrases
- combination therapy
- benign prostatic hyperplasia
- lower urinary tract symptoms
- end stage renal disease
- newly diagnosed
- ejection fraction
- prostate cancer
- chronic kidney disease
- minimally invasive
- peritoneal dialysis
- coronary artery bypass
- stem cells
- coronary artery disease
- skeletal muscle
- metabolic syndrome
- weight loss
- percutaneous coronary intervention
- adverse drug
- glycemic control